PROCEPT BioRobotics (NASDAQ:PRCT) CEO Larry Wood Purchases 23,900 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) CEO Larry Wood purchased 23,900 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares in the company, valued at $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

PROCEPT BioRobotics Stock Performance

PRCT opened at $20.41 on Monday. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $42.71. The company has a market capitalization of $1.16 billion, a P/E ratio of -10.52 and a beta of 0.89. The stock’s fifty day moving average is $21.59 and its two-hundred day moving average is $24.75. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. During the same period in the previous year, the company posted ($0.35) EPS. PROCEPT BioRobotics’s revenue for the quarter was up 19.3% on a year-over-year basis. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: PROCEPT reported quarterly revenue of $94.5 million, ahead of the $92.8 million consensus estimate, with year-over-year growth of 19.3%. The revenue beat helped support the shares despite a modest earnings miss. PROCEPT gains after Q2 beat; Wells Fargo downgrades
• Neutral Sentiment: PROCEPT posted an adjusted loss of $0.47 per share, narrowly worse than the $0.46 consensus estimate. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.53 per share.
• Negative Sentiment: Wells Fargo downgraded PROCEPT to Equal Weight, adding pressure after the earnings report and signaling limited near-term upside in the firm’s view. Wells Fargo downgrades PROCEPT BioRobotics to Equal Weight
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024 through February 25, 2026. The allegations concern weaker-than-expected handpiece sales and excess customer inventory allegedly created by late-quarter bulk discounts. The reports reference an approximately 18% stock decline and larger losses from the class-period high. The allegations have not been proven. PROCEPT securities fraud class action
• Negative Sentiment: Investors have been notified that September 22, 2026 is the lead-plaintiff deadline, increasing visibility around potential litigation costs, disclosure concerns and reputational risk. PROCEPT shareholder alert and lead plaintiff deadline

Hedge Funds Weigh In On PROCEPT BioRobotics

Several large investors have recently made changes to their positions in PRCT. BlackRock Inc. purchased a new stake in PROCEPT BioRobotics in the 2nd quarter valued at $109,961,000. Prosight Management LP grew its stake in shares of PROCEPT BioRobotics by 1,692.4% in the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after acquiring an additional 1,303,009 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after acquiring an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after purchasing an additional 1,218,815 shares during the period. Finally, UBS Group AG grew its stake in PROCEPT BioRobotics by 129.3% during the 3rd quarter. UBS Group AG now owns 944,545 shares of the company’s stock worth $33,711,000 after purchasing an additional 532,530 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on PRCT. Jefferies Financial Group reaffirmed a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday. Truist Financial set a $21.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday. Piper Sandler cut their price target on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday. TD Cowen reduced their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Leerink Partners cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $31.00 to $29.00 in a report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.